复发性或转移性头支状细胞癌的组合免疫化疗:系统性审查和元分析
Qiudong Xu1,2, Shuang Huang2, Kai Yang3
1Department of Oral and Maxillofacial Surgery, Wuxi Stomatology Hospital, Wuxi, China.
BMJ open
|June 13, 2023
概括
组合免疫化学疗法显著改善了复发性或转移性头支状细胞癌 (R/M HNSCC) 的生存率和反应率. 然而,它也增加了严重不良事件的发生率 (III和IV级).
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 免疫治疗是一种免疫疗法.
背景情况:
- 复发性或转移性头支状细胞癌 (R/M HNSCC) 是一个重大的治疗挑战.
- 传统的化疗对R/M HNSCC具有有限的疗效.
结论:
- 组合免疫化学疗法在改善R/M HNSCC的生存结果和反应率方面表现出卓越的疗效.
- 与联合免疫化学疗法相关的严重不良事件的风险增加需要仔细考虑和监测.
相关概念视频
01:27Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K